Cost-benefit analysis of medical vs surgical treatment of symptomatic patients with accessory atrioventricular pathways

R. Lezaun, P. Brugada, J. Smeets, M. Talajic, H. J. Trappe, P. Della Bella, R. Mulleneers, O. C K M Penn, H. J J Wellens

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Surgical treatment of patients with an accessory atrioventricular pathway leading to symptomatic arrhythmias provides effective control. However, surgical treatment is usually considered only when medical treatment fails. To assess the cost-benefit ratio of medical vs surgical treatment 77 patients treated with antiarrhythmic drugs were compared with 50 patients treated surgically. Cost was calculated by considering current costs for drugs, surgery and pacemakers, electrophysiological investigations, outpatient clinic controls, and costs of readmissions because of tachycardia. Mean cost per treated patient and mean cost per successfully treated patient (total cost divided by the number of patient not requiring readmission during follow-up) was respectively 4242 and 6949 US dollars after 56 months for the medically treated group and 10800 and 11250 US dollars for the surgically treated group. A projection of costs demonstrated that costs of medical treatment was the same as costs of surgical treatment after 12.5 years of treatment but a higher number of medically treated patients remain symptomatic. We conclude that surgical treatment of symptomatic patients with accessory pathways has a better cost-benefit ratio than medical treatment and should be considered earlier without waiting for failure for medical treatment.

Original languageEnglish
Pages (from-to)1105-1109
Number of pages5
JournalEuropean Heart Journal
Volume10
Issue number12
Publication statusPublished - Dec 1989

Fingerprint

Accessory Atrioventricular Bundle
Cost-benefit Analysis
Cost benefit analysis
Accessories
Cost-Benefit Analysis
Pathway
Costs
Costs and Cost Analysis
Therapeutics
Health Care Costs
Drug Costs
Cost-benefit analysis
Cost Control
Anti-Arrhythmia Agents
Antiarrhythmic Drugs
Patient treatment
Ambulatory Care Facilities
Treatment Failure
Tachycardia
Pacemakers

Keywords

  • Cost-benefit analysis
  • Surgical treatment
  • Wolff-Parkinson-White syndrome

ASJC Scopus subject areas

  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Physiology (medical)
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Lezaun, R., Brugada, P., Smeets, J., Talajic, M., Trappe, H. J., Bella, P. D., ... Wellens, H. J. J. (1989). Cost-benefit analysis of medical vs surgical treatment of symptomatic patients with accessory atrioventricular pathways. European Heart Journal, 10(12), 1105-1109.

Cost-benefit analysis of medical vs surgical treatment of symptomatic patients with accessory atrioventricular pathways. / Lezaun, R.; Brugada, P.; Smeets, J.; Talajic, M.; Trappe, H. J.; Bella, P. Della; Mulleneers, R.; Penn, O. C K M; Wellens, H. J J.

In: European Heart Journal, Vol. 10, No. 12, 12.1989, p. 1105-1109.

Research output: Contribution to journalArticle

Lezaun, R, Brugada, P, Smeets, J, Talajic, M, Trappe, HJ, Bella, PD, Mulleneers, R, Penn, OCKM & Wellens, HJJ 1989, 'Cost-benefit analysis of medical vs surgical treatment of symptomatic patients with accessory atrioventricular pathways', European Heart Journal, vol. 10, no. 12, pp. 1105-1109.
Lezaun, R. ; Brugada, P. ; Smeets, J. ; Talajic, M. ; Trappe, H. J. ; Bella, P. Della ; Mulleneers, R. ; Penn, O. C K M ; Wellens, H. J J. / Cost-benefit analysis of medical vs surgical treatment of symptomatic patients with accessory atrioventricular pathways. In: European Heart Journal. 1989 ; Vol. 10, No. 12. pp. 1105-1109.
@article{f8a15ff0d856412caddf01a70d23ad6c,
title = "Cost-benefit analysis of medical vs surgical treatment of symptomatic patients with accessory atrioventricular pathways",
abstract = "Surgical treatment of patients with an accessory atrioventricular pathway leading to symptomatic arrhythmias provides effective control. However, surgical treatment is usually considered only when medical treatment fails. To assess the cost-benefit ratio of medical vs surgical treatment 77 patients treated with antiarrhythmic drugs were compared with 50 patients treated surgically. Cost was calculated by considering current costs for drugs, surgery and pacemakers, electrophysiological investigations, outpatient clinic controls, and costs of readmissions because of tachycardia. Mean cost per treated patient and mean cost per successfully treated patient (total cost divided by the number of patient not requiring readmission during follow-up) was respectively 4242 and 6949 US dollars after 56 months for the medically treated group and 10800 and 11250 US dollars for the surgically treated group. A projection of costs demonstrated that costs of medical treatment was the same as costs of surgical treatment after 12.5 years of treatment but a higher number of medically treated patients remain symptomatic. We conclude that surgical treatment of symptomatic patients with accessory pathways has a better cost-benefit ratio than medical treatment and should be considered earlier without waiting for failure for medical treatment.",
keywords = "Cost-benefit analysis, Surgical treatment, Wolff-Parkinson-White syndrome",
author = "R. Lezaun and P. Brugada and J. Smeets and M. Talajic and Trappe, {H. J.} and Bella, {P. Della} and R. Mulleneers and Penn, {O. C K M} and Wellens, {H. J J}",
year = "1989",
month = "12",
language = "English",
volume = "10",
pages = "1105--1109",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Cost-benefit analysis of medical vs surgical treatment of symptomatic patients with accessory atrioventricular pathways

AU - Lezaun, R.

AU - Brugada, P.

AU - Smeets, J.

AU - Talajic, M.

AU - Trappe, H. J.

AU - Bella, P. Della

AU - Mulleneers, R.

AU - Penn, O. C K M

AU - Wellens, H. J J

PY - 1989/12

Y1 - 1989/12

N2 - Surgical treatment of patients with an accessory atrioventricular pathway leading to symptomatic arrhythmias provides effective control. However, surgical treatment is usually considered only when medical treatment fails. To assess the cost-benefit ratio of medical vs surgical treatment 77 patients treated with antiarrhythmic drugs were compared with 50 patients treated surgically. Cost was calculated by considering current costs for drugs, surgery and pacemakers, electrophysiological investigations, outpatient clinic controls, and costs of readmissions because of tachycardia. Mean cost per treated patient and mean cost per successfully treated patient (total cost divided by the number of patient not requiring readmission during follow-up) was respectively 4242 and 6949 US dollars after 56 months for the medically treated group and 10800 and 11250 US dollars for the surgically treated group. A projection of costs demonstrated that costs of medical treatment was the same as costs of surgical treatment after 12.5 years of treatment but a higher number of medically treated patients remain symptomatic. We conclude that surgical treatment of symptomatic patients with accessory pathways has a better cost-benefit ratio than medical treatment and should be considered earlier without waiting for failure for medical treatment.

AB - Surgical treatment of patients with an accessory atrioventricular pathway leading to symptomatic arrhythmias provides effective control. However, surgical treatment is usually considered only when medical treatment fails. To assess the cost-benefit ratio of medical vs surgical treatment 77 patients treated with antiarrhythmic drugs were compared with 50 patients treated surgically. Cost was calculated by considering current costs for drugs, surgery and pacemakers, electrophysiological investigations, outpatient clinic controls, and costs of readmissions because of tachycardia. Mean cost per treated patient and mean cost per successfully treated patient (total cost divided by the number of patient not requiring readmission during follow-up) was respectively 4242 and 6949 US dollars after 56 months for the medically treated group and 10800 and 11250 US dollars for the surgically treated group. A projection of costs demonstrated that costs of medical treatment was the same as costs of surgical treatment after 12.5 years of treatment but a higher number of medically treated patients remain symptomatic. We conclude that surgical treatment of symptomatic patients with accessory pathways has a better cost-benefit ratio than medical treatment and should be considered earlier without waiting for failure for medical treatment.

KW - Cost-benefit analysis

KW - Surgical treatment

KW - Wolff-Parkinson-White syndrome

UR - http://www.scopus.com/inward/record.url?scp=0024787790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024787790&partnerID=8YFLogxK

M3 - Article

C2 - 2514099

AN - SCOPUS:0024787790

VL - 10

SP - 1105

EP - 1109

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 12

ER -